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doi:10.1016/j.jfma.2012.01.018Background/Purpose: To study the outcome of a group of patients with schizophrenia receiving
community home care case management programs by delineating the relationship among their
psychopathology, rehospitalization rates and health-related quality of life (HRQoL).
Methods: This is a cross-sectional study on HRQoL, functioning and associating factors and
a retrospectivehistorical control study by comparing the frequency and duration of rehospita-
lization in a sample of 60 patients with schizophrenia under nonintensive case management
(non-ICM) in Taiwan. All participants were assessed on the Positive and Negative Syndrome
Scale for Schizophrenia (PANSS) for psychopathology, on EuroQoL-5D (EQ-5D) and EQ visual
analogue (EQ-VAS) for HRQoL, andGlobal Assessment of Functioning (GAF) for socio-
occupational dysfunction. Other clinical characteristics are also gathered.
Results: Patients with schizophrenia treated with non-ICM had a significant reduction in admis-
sion frequency (0.10  0.36 times per year, p Z 0.042) and length of inpatient stay
(e27.8  78.0 days per year, pZ 0.008). Better EQ-5D and EQ-VAS are significantly associated
with lower general psychopathology score, while better EQ-VAS is significantly associated with
older age and higher negative symptoms subscale score. GAF is negatively associated with
higher positive symptoms and negative symptoms subscale scores, while positively correlated
with a greater reduction in number and frequency of admission.
Conclusion: Non-ICM can help to decrease rehospitalization of home care patients. HRQoL and
functioning can be assessed by the three perspectives we used, and each measure wasof Psychiatry, National Taiwan University Hospital, 7 Chung Shan South Road, Taipei 10002, Taiwan.
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Quality of life in schizophrenia under home care CM 209correlated to different dimensions of patient psychopathology. It will be better if we include
baseline and post-intervention PANSS scores, HRQoL and functioning as outcome indicators.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Schizophrenia is a chronic, debilitating mental disorder that
affects approximately 1% of the general population1 and
causes impairments in patient functioning, such as self-care,
interpersonal relationships, and occupational skills.2e4
Health-related quality of life (HRQoL),5 an outcome mea-
surement obtained by a self-report of physical, emotional,
mental and functional wellbeing,6 has been applied to
patients with schizophrenia7,8 and they showed lower HRQoL
compared to the general population.9e11 Determinants
associated with worse HRQoL for patients with schizophrenia
included younger age of onset,12,13 positive symptoms,2,14,15
anxiety,14e17 depression,14e16,18,19 general psychopa-
thology,15,20,21 negative syndrome,2,15,20,21 and neuro-
cognitive deficits.2 Factors associated with better HRQoL
included older age,22 and use of second-generation antipsy-
chotics.23 However, there are also studies showing no relation
between positive,20,21,24,25 negative25 or depressive24 symp-
toms and HRQoL. These conflicting results are attributable to
patient selection, sample size, study design, characteristics
of settings and different measures.26
Past studies regarding HRQoL among patients with
schizophrenia focus on outpatient clinic, inpatients or an
unspecified population.2,21,22,26 Relatively few studies have
examined HRQoL of patients with schizophrenia receiving
community home visit programs.10,11,27 Lempp and
colleagues recruited people with schizophrenia treated by
community psychiatric teams in four sites in Europe. They
found that patients with schizophrenia had impaired
HRQoL, measured by the short form health survey (SF-36),
in physical and mental domains compared to the general
population. However, they did not evaluate schizophrenia
treatment course or symptom severity.10 Malakouti and
colleagues recruited individuals with schizophrenia
receiving home visit services. After 12 months of case
management, patients had significant improvement in
HRQoL measured by the Wisconsin Quality of Life system, as
well as reduced admission times. However, they focused on
clinical outcomes and did not analyze the association
between quality of life and clinical characteristics.27
According to the 2011 Cochrane review, either assertive
community treatment (ACT) or case management (CM)
providing care at home or places of work, an assertive
outreach, multidisciplinary team with a caseload of no
more than 20 patients is defined as intensive case
management (ICM).28 Both studies employed the ICM
model, while theevidence regarding HRQoL and its deter-
minants among patients with schizophrenia treated with
a non-ICM model (CM with a caseload of over 20 people)
remains limited.11
ICM or non-ICM is usually indicated for schizophrenia
patients who have poor drug compliance, frequent relapses
or repeated hospitalization.Compared with standard care,ICM is associated with shorter stays in hospital and works
best for frequently hospitalized patients.28,29 Non-ICM is
different from ICM in that it has a caseload of over 20
people. It is likely to be a common practice in places where
limited expenditure has been allocated to community care.
However, no study has examined the impact of non-ICM.28In
Taiwan, previously many schizophrenia patients tended to
be repeatedly hospitalized in acute or chronic ward settings
instead of returning to their communities. Recently
implementation of home treatment programs was encour-
aged by the Department of Health as a tertiary care model,
especially in areas that are not resourceful in mental
healthcare. In this study, we examine associations among
clinical outcomes and HRQoL in a sample of 60 patients with
schizophrenia treated with non-ICM in Taiwan. We
hypothesized that, first, schizophrenia patients treated
with non-ICM have significant clinical improvements, as
indicated by a reduction in need for hospitalization;
second, better quality of life and functioning are associated
with less severe psychopathology and fewer rehospitaliza-
tion after receiving non-ICM.Materials and methods
Study design
This study was carried out in the Department of Psychiatry,
Yun-Lin Branch of National Taiwan University Hospital
(NTUH) in Taiwan. The study was approved by a Human
Subjects Review Committee of NTUH. Yun-Lin is an agri-
cultural county with a population of 723,700 located in the
western part of Taiwan. Yun-Lin Branch of NTUH is one of
the few local hospitals providing medical support to this
relatively less resourceful county.The non-intensive case
management (non-ICM) program of the hospital consists of
a multidisciplinary team including trained psychiatrists,
psychiatric nurses, and social workers. It is indicated for
chronic psychotic patients who have poor drug compliance,
frequent relapses or repeated hospitalization. We provide
two face-to-face sessions per month at home or in places of
work to evaluate clinical symptoms, adverse drug reactions
and social functioning, to check medication compliance, to
engage uncooperative clients, to offer the patient and their
family psycho-education and counseling, as well as to
remind them of our regular service hours, telephone
numbers and the 24-hour emergency coverage provided by
the hospital.
The study design is a combination of a cross-sectional
assessment for quality of life and psychopathology and
a retrospectivehistorical control study for comparing clin-
ical improvement. A total of 130 patients with severe
mental illness are currently enrolled in this non-ICM
program. For this study, we only included participants
210 L.-R. Chang et al.who met the following criteria: (a) DSM-IV diagnosis of
schizophrenia; (b) absence of comorbid major depressive or
manic episodes, mental retardation, organic brain
syndrome, hypertension, diabetes mellitus, and other
major systemic diseases; and (c) absence of alcohol abuse
or any illicit substance use.In total 60 patients were eligible
and all of them provided informed voluntary, written
consent for us to collect their clinical data and be evalu-
ated for current psychopathology, quality of life and socio-
occupational functioning.Measurement instruments
Positive and Negative Syndrome Scale (PANSS)
Severity of psychopathologic symptoms was evaluated with
the Positive and Negative Syndrome Scale (PANSS) 30 by
a board-certified psychiatrist (LRC). PANSS includes positive
symptoms subscale score, negative symptoms subscale score,
and general psychopathology score. It is a semi-structured
interview based on information related to the past week,
with 30 items on a one- to seven-point continuum. Higher
scores reflect a greater severity of psychotic symptoms.
EuroQoL-5D (EQ-5D)
EuroQoL-5D (EQ-5D) is a self-reporting questionnaire
measuring five dimensions of an individual’s health state:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension has three levels of
severity, reflecting “no health problems”, “moderate
health problems”, and “extreme health problems”. The
composite scores are then transformed to an EQe5D time
trade-off index (TTO) which is generated based on hypo-
thetical trade-offs between length of life and symptoms. A
TTO value of 1 means full health and a value of 0 means
death. This index system has been validated in assessing
and measuring the HRQoL of patients with schizo-
phrenia.31e33 We used a Chinese version of EQe5D which
has been validated in a nonschizophrenic population.34
Patients were also asked to rate their health on the visual
analogue scale (VAS), a vertical scale where one endpoint is
labeled “Best imaginable health state” (indicating 100
points) and the other endpoint is labeled “Worst imaginable
health state” (indicating 0 points).
Global Assessment of Functioning (GAF)
The objective evaluation of patients’ overall socio-
occupational functioning was based on the Global Assess-
ment of Functioning (GAF) score, which was measured by
the same psychiatrist.1 The range of GAF score is between
0 and 100. A higher score means better functioning, while
a lower score means poorer functioning.
Clinical improvement
The assessment of clinical improvement includes the
number of admissions and the length of inpatient stay
before and after receiving our case management program;
that is from onset of schizophrenia to being enrolled in our
non-ICM program and from enrollment to the date of study
recruitment. We also calculated frequency of admissions
(defined as number of psychiatric admissions per year),
average length of inpatient stay (days of inpatient stay peryear), and the difference between the number and
frequency of admissions before and after receiving non-
ICM, as well as the difference between total and average
length of inpatient stay before and after receiving non-ICM.
Additional information
Demographic data (age, education, marital status), medical
conditions [body mass index (BMI), waist circumference],
current psychotropic medications (type of antipsychotics,
total chlorpromazine equivalent dose, benzodiazepines,
anticholinergics, b-blockers, antidepressants, mood stabi-
lizers use), and Clinical Global Impression-Severity (CGI-S)
were all collected.
Statistical analyses
All statistical tests were carried out using the SPSS version
15.0 for Windows (SPSS, Chicago, IL, USA). Descriptive
statistics for the total sample were performed to categorize
the patients in terms of clinical and psychosocial charac-
teristics. Four clinical improvement variables (admission
times, admission frequency, total length of inpatient stay,
and average length of inpatient stay) before and after
receiving non-ICM were compared by paired t test. We used
Pearson correlation coefficients to examine the associa-
tions between HRQoL, functioning and other clinical char-
acteristics. For categorical variables, such as gender,
educational level, marriage, employment and medication,
we treated patients as dummy variables taking on the
values 1 and 0. Subsequently, multivariate stepwise
regression analysis with stepwise method was performed to
find out predictors of HRQoL and functioning. We treated
EQ-TTO, EQ-VAS or GAF as dependent variables and put
age, gender and PANSS subscale scores (positive symptoms
subscale score, negative symptoms subscale score, and
general psychopathology score) as independent variables.
Statistical significance was assumed for p < 0.05. Values are
expressed as means  standard deviation (SD).
Results
Patient demographics, psychopathology,
functioning and quality of life
The demographic and psychopathological characteristics of
the participants are summarized in Table 1. Characteristi-
cally they were middle-aged (44.3  9.9 years; range 23e64
years) with long duration of illness (20.0  8.8 years; range
5e46 years) and had been enrolled in non-ICM for
41.5  35.0 months. Most patients (76.7%) had education
level at junior high school or below. Only 14 (23.3%)
patients were married or cohabiting and nine (15%) were
employed. Their average total PANSS score was 65.7.
19.2. Their average GAF was 45.2  7.1, EQ-TTO was
0.8  0.2 and EQ-VAS was 66.7  21.5.
Clinical features
The majority of our patients (71.7%) received a second-
generation antipsychotic at a relatively low dosage
Table 1 Demographic and psychopathological character-
istics of the study participants (n Z 60).
Age (y) 44.3  9.9
Gender
Male 27 (45.0)
Female 33 (55.0)
Education
College and above 2 (3.3)
Senior high school 12 (20.0)
Junior high school and below 46 (76.7)
Martial status
Unmarried 27 (45.0)
Married or cohabiting 14 (23.3)
Divorced, separated, or widowed 19 (31.7)
Job
Employed 9 (15)
Unemployed 51 (85)
Body mass index (kg/m2) 26.3  4.9
Onset of illness (y) 24.3  7.3
Length of illness (y) 20.0  8.8
Duration of non-ICM (mo) 41.5  35.0
Psychiatric admissions 3.0  3.3
Length of inpatient stay (d) 219.1  311.0
Medication
First-generation antipsychotic 17 (28.3)
Second-generation antipsychotic 43 (71.7)
Benzodiazepines 42 (70.0)
Anticholinergics 28 (46.7)
b-blockers 13 (21.7)
Antidepressants 8 (13.3)
Mood stabilizers 5 (8.3)
Antipsychotic dose (chlorpromazine
equivalent dose) (mg/day)
267.8  276.8
PANSS scores
Positive symptoms subscale score 15.3  5.0
Negative symptoms subscale score 19.7  8.1
General psychopathology score 30.8  9.1
Total score 65.7  19.2
CGI-Severity Scale 4.3  1.1
GAF 45.2  7.1
EQ-TTO 0.8  0.2
EQ-VAS 66.7  21.5
Data are presented as mean  SD or n (%).
CGI Z Clinical Global Impression; GAF Z Global Assessment of
Functioning; non-ICM Z nonintensive case management;
PANSS Z Positive and Negative Syndrome Scale; TTO Z trade-
off index; VAS Z visual analogue.
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tended to be overweight (BMI 26.3  4.9 kg/m2). Table 2
shows the differences in number of admissions, frequency
of admissions (times per year), length of inpatient stay, and
average length of inpatient stay (days per year) before and
after enrolment in our case management program. All of
these four indicators significantly decreased after receiving
non-ICM.Correlates of HRQoL and functioning
Participants’ subjective HRQoL measured by EQ-TTO was
negatively correlated with positive symptoms subscale
score, negative symptoms subscale score, general psycho-
pathology score, PANSS total scale, and CGI-Severity to
a statistically significant extent, while EQ-VAS was posi-
tively correlated with age, BMI, and length of illness yet
having no significant correlation with their clinical
psychopathology (Table 3). Objectively participants’ socio-
occupational functioning measured by GAF was positively
correlated with being employed, greater reduction in
number of admission and frequency of admission, and
negatively correlated with use of second-generation anti-
psychotic, antidepressants or mood stabilizers, and higher
scores in all PANSS subscales, PANSS total scale, and CGI-
Severity.
Multivariate regression analysis of HRQoL and
functioning
Adjusting for age, gender and PANSS subscale scores,
a multivariate linear regression with stepwise method was
performed to explore effects of each independent variable
on HRQoL and functioning. Table 4 shows that higher EQ-
TTO is significantly associated with lower general psycho-
pathology score (p < 0.001), while higher EQ-VAS is signif-
icantly associated with older age (p Z 0.01), higher
negative symptoms subscale score (p Z 0.03) and nega-
tively associated with general psychopathology score
(p Z 0.001). GAF is negatively associated with higher
positive symptoms subscale scores (p Z 0.001) and nega-
tive symptoms scores (p Z 0.011).
Discussion
Our findings support the hypothesis that schizophrenia
patients under nonintensive case management could gain
significant clinical benefits, as indicated by reduction in the
frequency of admission (times per year) and average length
of annual inpatient stay (days per year) (Table 2). This is
consistent with previous studies regarding either ICM or
non-ICM programs.27,28 Repeated hospitalization is one of
the major indications for enrolment in case management
programs. In countries with limited resources for providing
ACT, case management provided by community mental
health teams may support people with serious mental
illnesses as effectively as ACT teams.35 However, a decline
in case load alone, such as ICM, does not improve outcome
for severely psychotic patients36,37 and ICM is less
successful when inpatient use is already low.29 In our study
patients under this non-ICM saved about 4 weeks of hospi-
talization per year (Table 2), thus with regard to cost-
effectiveness, instead of ACT and ICM, non-ICM seems to
be a plausible alternative.
Also consistent with our expectation, better HRQoL and
functioning is associated with the severity of psychopa-
thology. Additionally we found that each of the three
measures we employed is correlated to different dimen-
sions of psychopathology. EQ-TTO, a subjective score to
estimate from five dimensions (mobility, self-care, usual
Table 2 Comparisons of frequency and duration of inpatient stay: before and after non-ICM (n Z 60).
Before non-ICM After non-ICM D (After e Before) t p
Psychiatric admissions 2.57  2.75 0.47  1.23 2.10  2.67 6.101 0.000
Frequency of admissions (per year) 0.22  0.26 0.13  0.31 0.10  0.36 2.076 0.042
Duration of inpatient stay (d) 182.7  278.1 36.4  89.4 146.3  271.9 4.168 0.000
Annual inpatient time (d/year) 48.8  65.0 21.0  59.0 27.8  78.0 2.762 0.008
The duration of follow-up period before and after non-ICM was 192.0  98.4 months and 41.5  35.0 months, respectively. Data are
presented as mean  SD.
Non-ICM Z non-intensive case management; D Z difference.
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a patient’s quality of life, is negatively correlated to all
three dimensions in PANSS subscale scores (Table 3). Such
an association between better EQ-TTO and lower general
psychopathology score persisted when we examined by
multivariate regression analysis (Table 4). Although another
subjective rating by EQ-VAS did not show significant
correlations by testing it alone (Table 3), and EQ-VAS also
revealed such a negative association between quality of lifeTable 3 Correlates of health-related quality of life and functio
Age
Gender (F Z 0, M Z 1)
Educational level (below junior high school Z 0, above Z 1)
Marriage (single, divorced, widowed Z 0, married, cohabitating
Job (No Z 0, Yes Z 1)
Body mass index
Onset of illness
Length of illness
Duration of home care
Psychiatric admissions
Length of inpatient stay
D Psychiatric admissions
D Frequency of admissions
D Length of inpatient stay
D Average length of inpatient stay
Medication (No Z 0, Yes Z 1)
Second-generation antipsychotics
Benzodiazepines
Anticholinergics
b-blockers
Antidepressants
Mood stabilizers
Antipsychotic dose (chlorpromazine equivalent dose)
PANSS scores
Positive symptoms subscale score
Negative symptoms subscale score
General psychopathology score
Total score
CGI-Severity Scale
* p < 0.05.
** p < 0.01.
CGIZ Clinical Global Impression; GAFZ Global Assessment of Functio
and Negative Syndrome Scale; TTOZ trade-off index; VASZ visual aand general psychopathology score in regression analyses
(Table 4). These findings are consistent with previous
results that general psychopathology is associated with
poorer HRQoL.15,20,21
Interestingly, our results revealed that better EQ-VAS is
associated with higher, rather than lower, negative symp-
toms subscale score, which seems to go contrary to
previous findings that more negative symptoms are associ-
ated with a poorer quality of life.2,15,20,21 One might arguening (n Z 60).
EQ-TTO EQ-VAS GAF
0.165 0.274* 0.164
0.076 0.127 0.090
0.117 0.196 0.012
Z 1) 0.204 0.105 0.033
0.184 0.054 0.354**
0.041 0.276* 0.016
0.192 0.058 0.020
0.025 0.259* 0.201
0.031 0.019 0.198
0.065 0.133 0.154
0.228 0.065 0.069
0.083 0.096 L0.470**
0.024 0.017 L0.488**
0.217 0.057 0229
0.088 0.025 0.101
0.031 0.040 L0.295*
0.154 0.069 0.085
0.091 0.071 0.143
0.161 0.052 0.188
0.105 0.003 0.292*
e0.425** 0.073 L0.304*
0.041 0.037 0.245
L0.426** 0.195 L0.529**
L0.331** 0.009 L0.466**
L0.581** 0.256 L0.405**
L0.527** 0.169 L0.528**
L0.438** 0.126 L0.432**
ning; non-ICMZ nonintensive case management; PANSSZ Positive
nalogue; DZ difference (after e before non-ICM).
Table 4 Stepwise linear regression with age, gender and PANSS scores predicting health-related quality of life and functioning
(n Z 60).
Predictor B Adjusted
R square value
F value Significance 95% Confidence
interval of B
EQ-TTO 0.326 29.543 <0.001
General psychopathology score 0.015 <0.001 (0.020, 0.009)
EQ-VAS 0.190 5.523 0.002
Age 0.690 0.010 (0.173, 1.207)
General psychopathology score 1.293 0.001 (2.067, 0.518)
Negative symptoms subscale score 0.956 0.030 (0.096, 1.817)
GAF 0.334 15.804 <0.001
Positive symptoms subscale score 0.579 0.001 (0.909, 0.250)
Negative symptoms subscale score 0.267 0.011 (0.471, 0.062)
PANSS Z Positive and Negative Syndrome Scale; TTO Z trade-off index; VAS Z visual analogue.
Quality of life in schizophrenia under home care CM 213that EQ-VAS is an intuitive rating without much discretion
and simply reflects a vague, subjective sense of well-being.
Thus it is possible that patients with prominent negative
symptoms are not aware of their lower-than-average
mobility, self-care, usual activities etc, or their higher
satisfaction of life quality is indeed revealing their lower
motivation to change their current status. The positive
correlations between EQ-VAS and older age, longer length
of illness, as well as higher BMI provide indirect support to
this inference (Table 3).
Similar to EQ-TTO, GAF is also negatively correlated to
all three dimensions in PANSS subscale scores (Table 3).
In contrast, lower GAF score is associated with higher
positive and negative symptoms subscale scores, but not
with general psychopathology scores, in multivariate
regression analyses (Table 4). The presentation of delu-
sion, hallucination or other disorganized behaviors, as
well as negative symptoms may interfere with a patient’s
abilities to maintain self-care, interpersonal relations
and occupational skills,2e4 especially when the impact is
measured objectively by GAF. Moreover, higher GAF is
correlated to greater reduction in the number and
frequency of admission, but the use of second-
generation antipsychotic agents, antidepressants, and
mood stabilizers are all correlated to lower GAF. It seems
to suggest that if a patient needed to use these medi-
cations, they might have greater clinical severity and
poorer functioning in this less resourceful county. It is
not surprising at all that being employed is correlated to
a higher GAF.
There were no relations between HRQoL, functioning
and other clinical characteristics including educational
level, marital status, onset of illness, length of illness,
duration of non-ICM, or antipsychotic dose (chlorpromazine
equivalent dose). Narvaez and colleagues also found that
length of illness and antipsychotic dose (chlorpromazine
equivalent dose) are not associated with HRQoL.21
The present study has some limitations. First, we did not
include evaluation of neuro-cognitive functions, compli-
ance to medication and adverse reactions, which might be
confounding factors in HRQoL and functioning. Patient or
caregiver recall about onset of disease, times of admission,
and duration of admission in other psychiatric hospitals may
be biased, which could result in information bias. Second,we excluded comorbid medical or psychiatric conditions
that may interfere with the association between psycho-
pathology, HRQoL and functioning, yet rendered a medium
sample size not feasible for more statistical analyses. The
strict process of exclusion may also cause a selection bias.
The current sample might not be representative of schizo-
phrenia patients receiving non-ICM in general. Third, the
results of this non-ICM program could not be generalized to
other community settings or inpatient population of
schizophrenia. Fourth, EQ-5D is just one of the methods to
assess HRQoL and may not be comparable to other
measures. It does not include dimensions referring to social
relationships, quality of success of the activities or social
contacts, social skills performance and the like. Fifth,
regarding rehospitalization, our before-and-after study
design might exaggerate the impact of non-ICM interven-
tion, as certain improvement could be attributable to
concurrent changes in the society and general psychiatric
service in Taiwan. Finally, our study design did not include
comparison groups other than using historical controls. In
the future, the inclusion of patient groups treated as
regular outpatients or with other treatment modalities,
such as chronic inpatients, or residents in halfway house,
will be helpful to reveal the distinguishing features of home
visit case management.
In conclusion, non-ICM is an important ingredient of
a community mental healthcare system. Regardless of
resourcefulness, it is believed to be necessary to hospital
services in all areas.38 Practically EQ-5D can be employed
to assess the HRQoL of patients with schizophrenia easily
in community settings, although its degree of validity is
pending further study.39 EQ-VAS is likely to be a minor
complement to measure a patient’s subjective feelings
and should be interpreted with discretion. GAF gives
a reasonable objective rating which is well correlated to
reduction in rehospitalization, but not necessarily what
the patients are most concerned about. To study the
impact of a case management program or other psycho-
social approaches as an adjunctive therapy to pharmaco-
therapy, such as cognitive behavioral therapy, social skills
training, or supported employment, we suggest measuring
from all three perspectives and to include baseline and
postintervention psychopathology and HRQoL as outcome
indicators.
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